| 13.83 -0.67 (-4.62%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.98  |
1-year : | 26.23 |
| Resists | First : | 18.82 |
Second : | 22.45 |
| Pivot price | 15.17 |
|||
| Supports | First : | 12.93 | Second : | 10.76 |
| MAs | MA(5) : | 14.08  |
MA(20) : | 15.77 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1.7 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 22.2 |
D(3) : | 21.7 |
| RSI | RSI(14): 30.9 |
|||
| 52-week | High : | 28 | Low : | 12.93 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATTO ] has closed above bottom band by 24.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 14.76 - 14.84 | 14.84 - 14.88 |
| Low: | 13.36 - 13.46 | 13.46 - 13.52 |
| Close: | 13.69 - 13.84 | 13.84 - 13.93 |
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Sat, 24 Oct 2026
Attovia Therapeutics, Inc. Estimates – NASDAQ:ATTO - TradingView
Mon, 21 Sep 2026
Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still Fits - Yahoo Finance
Fri, 04 Sep 2026
Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO) - The Globe and Mail
Wed, 05 Aug 2026
Attovia Therapeutics Rings the Opening Bell - Nasdaq
Wed, 05 Aug 2026
Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders - MedCity News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 2.626e+007 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 649 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.525e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 845.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1.8e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 1.65e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|